AbCellera Biologics得到分析师的“Buy”评分, AbCellera Biologics receives a "Buy" rating from analysts despite negative margins and a $1.25 billion market cap.

AbCellera Biologics是一家抗体药物发现公司,从分析家那里获得了“Buy”共识评级,平均目标价格为8.00美元。 AbCellera Biologics, an antibody drug discovery firm, has received a "Buy" consensus rating from analysts, with an average target price of $8.00. 尽管出现负差,但该公司的Q4收入1 708万美元超过了预期。 Despite recording negative margins, the company's Q4 revenue of $17.08 million surpassed expectations. AbCellera的市场上限为12.5亿美元,其股票最近有不同的分析家评级,包括升级为“买”和“强购”。 AbCellera has a market cap of $1.25 billion and its stock has seen varied analyst ratings recently, including upgrades to "buy" and "strong buy."